title: Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study.
abstract: Calcium fructoborate (CFB) at a dose of 110 mg twice per day was previously reported to improve knee discomfort during the first 14 days of treatment. In this study, 60 participants with self-reported knee discomfort were randomized into two groups receiving CFB or placebo. Initial levels of knee discomfort were evaluated by Western Ontario and McMaster Universities Arthritis Index (WOMAC) and McGill Pain Questionnaire (MPQ) scores at the beginning of the study and also at 7 and 14 days after treatment. Results showed that supplementation with CFB significantly improved knee discomfort in the study subjects; significant reductions of mean within-subject change in WOMAC and MPQ scores were observed for the CFB group compared to the placebo group at both 7 and 14 days after treatment. Estimated treatment differences for the MPQ score were -5.8 (P=0.0009) and -8.9 (P<0.0001) at Day 7 and 14, respectively. Estimated differences for the WOMAC score were -5.3 (P=0.06) and -13.73 (P<0.0001) at Day 7 and 14, respectively. Negative values indicate greater reductions in reported discomfort. On both Day 7 and Day 14, the trend was toward greater improvement in the CFB group. The placebo group did not exhibit any change in the WOMAC and MPQ scores. In conclusion, supplementation with 110 mg CFB twice per day was associated with improving knee discomfort during the 2 weeks of intake.
authors.affiliation: FutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Pietrzkowski
authors.affiliation: Department of Statistics, School of Information and Computer Science, University of California at Irvine, CA, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Phelan
authors.affiliation: NutraClinical Inc., Irvine, CA, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Keller
authors.affiliation: FutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Shu
authors.affiliation: FutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
authors.forename: Ruby
authors.initials: R
authors.lastname: Argumedo
authors.affiliation: FutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
authors.forename: Tania
authors.initials: T
authors.lastname: Reyes-Izquierdo
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018771:Arthralgia / Q000188:drug therapy; D001881:Borates / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007719:Knee Joint / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D010147:Pain Measurement; D011795:Surveys and Questionnaires
chemical_list: D000893:Anti-Inflammatory Agents; D001881:Borates; C507177:calcium fructoborate; D005632:Fructose
keywords: CFB; McGill pain score; WOMAC score; joint discomfort